‘Missed Opportunity’: GSK Failed To Optimize Blenrep Dosage, US FDA Panel Says

 
• By Sue Sutter
Rifle target
Dosage questions and the small number of US patients in pivotal trials put Blenrep in OCE's crosshairs. (Shutterstock)

More from US Advisory Committees

More from Product Reviews